BioCentury | Dec 5, 2020
Translation in Brief

James Wilson developing gene therapy version of Regeneron COVID mAb cocktail; plus an oncolytic adenovirus, MapLight-Michael J. Fox Foundation and more

Penn, Regeneron on AAV-encoded REGN-COV2A James Wilson-led University of Pennsylvania team is developing a gene therapy form of casirivimab/imdevimab (REGN-COV2) from Regeneron Pharmaceuticals Inc. (NASDAQ:REGN). The collaboration is based on the potential for a single, intranasal...
BioCentury | Oct 27, 2020
Distillery Therapeutics

ZDHHC7 and LYPLA2 identified as targets in Crohn’s, ulcerative colitis

DISEASE CATEGORY: Autoimmune disease INDICATION: Inflammatory bowel disease (IBD); Crohn’s disease Inhibiting ZDHHC7 and LYPLA2 — two genes that regulate membrane localization of the...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Oct 8, 2020
Product Development

COVAX nears $2B fund-raising goal for equitable vaccine distribution; plus Novartis-Merck KGaA, 10x Genomics, Alkermes, UCB-Aetion, Janpix, BeiGene-BioAtla, Phenomic AI

COVAX nearing $2B fund-raising goal for equitable vaccine distributionThe U.K., Canada, Germany, Italy and Sweden pledged $958 million to Gavi’s COVID-19 Vaccines Advance Market Commitment (COVAX AMC), which seeks to ensure equitable access to COVID-19...
BioCentury | Sep 17, 2020
Deals

Awaiting dialogue with FDA on GI program, microbiome play Finch looks to autism, HBV with new $90M round

With one pivotal readout in Clostridium difficile already achieved, microbiome company Finch has tapped investors for a $90 million series D round that will fund additional programs, and potentially help...
BioCentury | Jun 27, 2020
Translation in Brief

Regeneron enhances checkpoint therapy with CD28 bispecifics; plus NIH funds Alzheimer’s brain mapping, Genentech and more

Regeneron combines CD28 bispecifics with PD-1 mAb In its latest paper covering anti-CD28 bispecific antibodies, Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) showed in Science Translational Medicine that the bispecifics could boost anti-PD-1 efficacy. Bispecifics against CD28 and...
BioCentury | Jun 27, 2020
Product Development

A mechanistic view of four compounds that disrupt interleukin pathways to treat severe COVID-19

Master protocols for COVID-19 clinical trials are testing half a dozen molecules that aim to prevent respiratory distress in patients with severe disease by targeting the host immune system -- four of these compounds intervene...
BioCentury | Jun 22, 2020
Emerging Company Profile

Prosit Sole: chimeric proteins for rare disease

Prosit Sole is improving upon protein and cytokine therapies against validated targets for rare diseases using its chimeric protein engineering platform. The idea is to combine desirable structural features from different protein family members to...
BioCentury | Jun 11, 2020
Product Development

Emerging COVID-19 serology tests aim for neutralizing antibodies

The next wave of serology tests from big diagnostic players could get closer to telling people whether they are protected from COVID-19 by homing in on the antibodies most likely to block viral entry into...
BioCentury | May 1, 2020
Distillery Therapeutics

Thioredoxin reducing enzyme inhibitors for solid tumors

DISEASE CATEGORY: Cancer INDICATION: Colorectal cancer; head and neck cancer; lung cancer A Karolinska Institute team has identified compounds that inhibit TXNRD1, a thioredoxin reductase, that could treat colorectal, hypopharyngeal and lung cancers. TXNRD1 regenerates...
Items per page:
1 - 10 of 396